Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments
July 19, 2017 16:01 ET
|
Sarepta Therapeutics
-- Achieved net revenue of $35 million for the second quarter 2017 -- -- Increased revenue guidance range to $125 – $130 million for the year – -- Entered into global settlement and license...
Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
July 19, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 19, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. biopharmaceutical company focused on the discovery and development of unique RNA-targeted...
Sarepta Therapeutics Secures $100 Million in Debt Financing
July 18, 2017 16:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation
July 18, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2017 18:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer
June 28, 2017 16:01 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017
June 28, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover
June 27, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy
June 21, 2017 07:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass. and EVRY, France, June 21, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2017 18:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...